Recursion has reported initial monotherapy dose-escalation data from the Phase I/II study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumours. These results were presented after market close at an AACR Special Conference in Cancer Research. “Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive… Read More
TechBio Recursion will be launching a Phase I/II clinical trial of REC-1245 for the treatment of biomarker-enriched solid tumours and lymphoma, following the go-ahead from the US Food and Drug Administration (FDA). REC-1245 is a potent and selective RBM39 degrader with a potential… Read More
Recursion has announced plans to open a new office in June 2024. The site will provide Recursion and Valence Labs, the company’s artificial intelligence (AI) research engine, with access to European talent and a life science ecosystem from which to work. Chris Gibson, Co-founder and CEO… Read More
Recursion, a clinical stage company decoding biology to industrialise drug discovery, has announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry,… Read More
